The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2022 | Updates on ZUMA-7: clinical and patient-reported outcomes in elderly patients with R/R LBCL
Jason Westin, MD, FACP, University of Texas MD Anderson Center, Houston, TX, gives an overview of the results of a subgroup analysis of the ZUMA-7 study evaluating axicabtagene ciloleucel (axi-cel) versus standard of care (SOC) therapy in second-line in elderly patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL; NCT03391466). Overall, the study demonstrated that axi-cel was more effective and better tolerated, with an improved quality of life (QoL), when compared to standard chemotherapy with autologous hematopoietic stem cell transplantation (autoHSCT). This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
